• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The registration and control of medicines in South Africa: legal issues.

作者信息

Folb P I

机构信息

University of Cape Town, South Africa.

出版信息

Med Law. 1991;10(6):555-63.

PMID:1822574
Abstract

In the provision of health care medicines occupy a central position, both at primary and more advanced levels. Sound medicines have the capability to control and prevent common diseases, and to alleviate suffering. People's confidence in the health services that are provided by the state and by the private sector (as the case may be) is influenced by their knowledge that the medicines that they receive are of good quality and proven efficacy and safety, and that they are continuously available at reasonable cost. A sound national policy for the provision of safe and cost-effective medicines needs to be based on several elements. The most important are: A sound pharmaceutical industry that is able to function in an atmosphere of confidence, with the knowledge that its efforts in support of the public health are understood and respected; and a drug regulatory authority that is trusted for its expertise, independence and integrity. This is as true for a country such as South Africa as it is for a fully industrialised country such as the United States. The regulation and control of medicines in South Africa falls under the aegis of the Medicines Control Council, a statutory body established in accordance with the Medicines and Related Substances Act. In terms of the Act, the council has the mandate to ensure that the medicines available to the South African public are safe, effective, and of high quality, and that their availability is in the public interest. In considering this, the council may take into account only the scientific data available.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
The registration and control of medicines in South Africa: legal issues.
Med Law. 1991;10(6):555-63.
2
How best to utilize limited resources.如何最好地利用有限资源。
J Hosp Infect. 1995 Jun;30 Suppl:15-25. doi: 10.1016/0195-6701(95)90002-0.
3
Fighting trafficking of falsified and substandard medicinal products in Russia.打击俄罗斯假药和劣药的非法交易。
Int J Risk Saf Med. 2015;27 Suppl 1:S37-40. doi: 10.3233/JRS-150681.
4
Regulatory crackdown on stem cell therapy: what would the position be in South Africa?对干细胞治疗的监管打击:南非的立场会是什么?
S Afr Med J. 2012 Mar 7;102(4):219-20.
5
AIDS: some medico-legal aspects.艾滋病:一些法医学方面的问题。
Med Law. 1991;10(2):139-53.
6
Drug quality in South Africa: perceptions of key players involved in medicines distribution.南非的药品质量:药品分销领域主要参与者的看法。
Int J Health Care Qual Assur. 2009;22(5):547-60. doi: 10.1108/09526860910975643.
7
American Society of Clinical Oncology policy statement: oversight of clinical research.美国临床肿瘤学会政策声明:临床研究监督
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
8
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
9
Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.迈向欧洲药品研究战略(2014-2020 年):欧盟制药工业协会联合会关于“地平线 2020”计划的立场文件。
Eur J Pharm Sci. 2012 Dec 18;47(5):979-87. doi: 10.1016/j.ejps.2012.09.020. Epub 2012 Oct 6.
10
Complementary medicines: When regulation results in revolution.补充医学:监管引发变革之时。
S Afr Med J. 2017 May 24;107(6):483-485. doi: 10.7196/SAMJ.2017.v107i6.12055.